# Granza Bio

Source: https://onco.cc/companies/granza-bio/  
OnCo record `granza-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Granza Bio is turning the natural attack particles that killer immune cells fire at their targets into programmable medicines that can re-arm exhausted immune cells against cancer.

## Summary

Granza Bio builds on the discovery of supramolecular attack particles, the cytotoxic granules that cytotoxic T cells and natural killer cells release to kill targets, and engineers them into programmable therapeutics that deliver localised cell killing and re-arm exhausted immune cells, with applications from cancer to autoimmunity. The company is an Oxford-linked spin-out based in San Francisco and is preclinical; no sourced financing rounds are recorded.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: yc
- HQ: San Francisco, CA
- Type: biotech
- Website: https://www.granzabio.com

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/granza-bio
- Official website: https://www.granzabio.com

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Cytokines & engineered cytokines](https://onco.cc/technologies/cytokine-therapy/)
- companies: [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/granza-bio.json